 difÔ¨Åcult and
complex than treatment of a failing but still patent graft.
Surveillance programs of lower extremity vein grafts may
be solely clinical or both clinical and vascular laboratory based.
The Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) working group recommended
patients treated with lower extremity vein grafts be monitored
for at least 2 years with a clinical surveillance program that
consists of an interval history to detect new symptoms, pulse